Cargando…

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis

Tuberous sclerosis syndrome (TSC) is an autosomal dominant tumor suppressor gene syndrome affecting multiple organs, including renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM). LAM is a female-predominant interstitial lung disease characterized by the progressive cyst formation and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chenggang, Zhang, Erik, Sun, Yang, Lee, Po-Shun, Zhan, Yongzhong, Guo, Yanan, Osorio, Juan C., Rosas, Ivan O., Xu, Kai-Feng, Kwiatkowski, David J., Yu, Jane J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210122/ https://www.ncbi.nlm.nih.gov/pubmed/25347447 http://dx.doi.org/10.1371/journal.pone.0104809

Ejemplares similares

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Lymphangioleiomyomatosis Associated with Tuberous Sclerosis Complex
por: Tanitame, Keizo
Publicado: (2020)

Tuberous sclerosis complex associated lymphangioleiomyomatosis
por: Han, Z, et al.
Publicado: (2023)

Pneumothorax as a Presentation of Tuberous Sclerosis-Associated Lymphangioleiomyomatosis
por: Silva, Duarte Lages, et al.
Publicado: (2019)

Lymphangioleiomyomatosis with Tuberous Sclerosis Complex—A Case Study
por: Marciniak, Aleksandra, et al.
Publicado: (2023)

Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis
por: Lamattina, Anthony M., et al.
Publicado: (2019)

A Case of Uterine Lymphangioleiomyomatosis Complicated by Tuberous Sclerosis Complex
por: Yamada, Kaori, et al.
Publicado: (2022)

Tuberous sclerosis complex presenting as pulmonary lymphangioleiomyomatosis - a clinicoradiological diagnosis
por: Gupta, Kamini, et al.
Publicado: (2015)

A Case of Tuberous Sclerosis Complex with Lymphangioleiomyomatosis and Renal Cell Carcinoma
por: Wu, Yun, et al.
Publicado: (2020)

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway
por: Hartman, Tiffiney R., et al.
Publicado: (2009)

Tuberous Sclerosis Complex Associated with Papillary Serous Carcinoma of the Peritoneum, Lymphangioleiomyomatosis, and Angiomyolipoma
por: Wakamiya, Tomihiro, et al.
Publicado: (2011)

A rare pulmonary lymphangioleiomyomatosis disease in a male with tuberous sclerosis complex
por: Kabi, Ankita, et al.
Publicado: (2020)

Leiomyomatosis-like lymphangioleiomyomatosis: A case report of the colonic manifestation of tuberous sclerosis
por: Erginoz, Ergin, et al.
Publicado: (2021)

Hyponatremia: A Tip of the Iceberg in the Late Diagnosis of Tuberous Sclerosis Associated With Lymphangioleiomyomatosis
por: Paiva, David, et al.
Publicado: (2021)

The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis
por: Delaney, Sean P., et al.
Publicado: (2014)

Tuberous sclerosis complex-lymphangioleiomyomatosis involving several visceral organs: A case report
por: Chen, Hong-Bin, et al.
Publicado: (2021)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
por: Lu, Yiyang, et al.
Publicado: (2020)

Computed tomographic findings of tuberous sclerosis with pulmonary lymphangioleiomyomatosis and renal angiomyolipomas: a case report
por: Vianna, Flavia Gavinho, et al.
Publicado: (2009)

Tuberous sclerosis with pulmonary lymphangioleiomyomatosis and renal angiomyolipomas. Computed tomographic findings: a case report
por: Vianna, Flávia G, et al.
Publicado: (2009)

Real-Time Monitoring of Tumorigenesis, Dissemination, & Drug Response in a Preclinical Model of Lymphangioleiomyomatosis/Tuberous Sclerosis Complex
por: Liu, Fangbing, et al.
Publicado: (2012)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Reprogramming patient-derived tumor cells generates model cell lines for tuberous sclerosis-associated lymphangioleiomyomatosis
por: Julian, Lisa M., et al.
Publicado: (2017)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

Exploring the Role of Matrix Metalloproteinases as Biomarkers in Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. A Pilot Study
por: Terraneo, Silvia, et al.
Publicado: (2021)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study
por: TEHRANI, Fateme, et al.
Publicado: (2023)

Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex
por: Guo, Yanan, et al.
Publicado: (2016)

Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis
por: Li, Xiangke, et al.
Publicado: (2017)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
por: Rosado, C., et al.
Publicado: (2013)

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
por: Lee, Nancy, et al.
Publicado: (2009)

COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition
por: Baldi, Bruno Guedes, et al.
Publicado: (2022)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
por: Mao, Shanshan, et al.
Publicado: (2017)

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin
por: Lu, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dmvno0ljnboodre65r2icvf39i